BeOne Medicines (ONCN) Income Statement
BeOne Medicines Income Statement
Last quarter (Q2 2026), BeOne Medicines's total revenue was $1.71B, an increase of 29.63% from the same quarter last year. In Q2, BeOne Medicines's net income was $237.01M. See BeOne Medicines’s key income statements, including revenue, expenses, profit, and income.
| Income Statement | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| $ 5.34B | $ 3.81B | $ 2.46B | $ 1.42B | $ 1.18B | |
| $ 4.67B | $ 3.22B | $ 2.08B | $ 1.13B | $ 1.01B | |
| $ 4.23B | $ 3.78B | $ 3.29B | $ 2.92B | $ 2.45B | |
| Depreciation and Amortization | $ 141.69M | $ 171.76M | $ 87.67M | $ 66.28M | $ 46.46M |
| $ 616.77M | $ -361.24M | $ -738.16M | $ -1.89B | $ -1.39B | |
| $ 447.14M | $ -568.20M | $ -1.21B | $ -1.79B | $ -1.44B | |
| $ -30.28M | $ 35.20M | $ 381.90M | $ -171.37M | $ 147.00K | |
| $ 416.85M | $ -533.00M | $ -825.84M | $ -1.96B | $ -1.44B | |
| $ 286.93M | $ -644.79M | $ -881.71M | $ -2.00B | $ -1.46B | |
| Per Share Metrics | |||||
| Basic EPS | $ 33.80 | $ -6.12 | $ -8.45 | $ -19.37 | $ -15.21 |
| Diluted EPS | $ 32.11 | $ -6.12 | $ -8.45 | $ -19.37 | $ -15.21 |
| Weighted Average Shares Outstanding | 109.06M | 105.29M | 104.39M | 103.13M | 92.79M |
| Weighted Average Shares Outstanding (Diluted) | 113.45M | 105.29M | 104.39M | 103.13M | 92.79M |
Currency in USD